Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Int Forum Allergy Rhinol. 2016 Jan 11;6(6):605–610. doi: 10.1002/alr.21704

Figure 5. HSNFs from patients with CRSwNP proliferate significantly more at baseline than HSNFs from control patients.

Figure 5

When treated with 1,25VD3 (50 pg/ml), there is a significant decrease in proliferation in patients with CRSwNP. Data shown is mean +/− SEM. Stats shown are results of post hoc analysis following one way ANOVA. N= 5 for control. N=3 for CRSwNP. Proliferation index is the average number of cells that one initial cell became. *p<0.01between indicated groups.